TWST

103.3207.44%
PJ

Patrick John Finn

President & COO

Dr. Patrick John Finn, also known as Paddy, Ph.D., had been Chief Commercial Officer of Twist Bioscience Corporation since October 24, 2019 until October 2022 and serves as its President and Chief Operating Officer since October 2022. He serves as an Independent Director of Oxford NanoImaging Limited (ONI). Dr. Finn served as Senior Vice President of Commercial Operations at Twist Bioscience Corporation from December 2018 to October 2019. He was Vice President of Sales and Marketing at Twist Bioscience Corporation since February 2015 until October 2019. Dr. Finn is a seasoned executive with many years of life sciences industry leadership. He has extensive experience commercializing new technologies. Dr. Finn was Vice President of Sales at Enzymatics Inc. from January 2012 to March 2015. He joined Twist Bioscience from Enzymatics (recently acquired by QIAGEN), where he was Vice President of sales and marketing, leading commercial activities for North America and Europe, delivering significant top line growth and expanding the base of business to business customers. Prior to Enzymatics, he has held positions with increasing commercial focus, including Director of Business Development at Agilent Technologies, Director of product development for Beckman Coulter Molecular Diagnostics, and multiple technical roles in product development within Invitrogen and GE Healthcare/Amersham International. He serves as a Member of Scientific Advisory Board at LaserGen, Inc. He served on the scientific advisory Board of Enzymatics. Dr. Finn holds a B.Sc. Hons in Chemistry from Heriot-Watt University. He received his Ph.D. in chemistry at Southampton University, UK, in 1996 for research investigating Peptide Nucleic Acid/DNA hybrid oligonucleotides and their physical properties.

Positions